Matches in Nanopublications for { ?s ?p "DDI between Natalizumab and Bleomycin - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants. [drugbank_resource:DB00108_DB00290]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00108_DB00290 label "DDI between Natalizumab and Bleomycin - Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants. [drugbank_resource:DB00108_DB00290]" assertion.